Allegro Dx Licenses IP from BU, University of Utah Foundation for Lung Cancer Test
July 05, 2011
Allegro Dx Licenses IP from BU, University of Utah Foundation for Lung Cancer Test
Allegro CEO Mike Webb said the licensing agreement will support the "continued advancement" of the firm's BronchoGen test, including a planned commercial launch in the first half of 2012.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Allegro Diagnostics Raises $5.4M to Advance Lung Cancer Test
July 19, 2011 / BioArray News - Allegro Licenses Lung Cancer Testing IP from Boston University, University of Utah Foundation
June 29, 2011 / GenomeWeb Daily News - BU Spinout AllegroDx to Launch Array-Based Lung Cancer Test This Year
January 5, 2010 / BioArray News - Q&A: INMEGEN's Alfredo Hidalgo on Using Genomics to Address Mexico's Most Pressing Health Problems
May 21, 2013 / BioArray News - Despite Continued Genotyping Growth, Weak Expression Sales Force Affymetrix to Suspend Guidance
May 7, 2013 / BioArray News